Factor Xa Inhibitors in CAD and Diabetes: Evaluating the Latest Data
- Latest clinical trial data on the use of combination anticoagulant and antiplatelet therapy in patients with CAD and diabetes;
- Clinical guidelines on the use of antithrombotic therapy in patients with CAD and diabetes.
Professor of Medicine
Harvard Medical School
Executive Director of Interventional Cardiovascular Programs
Brigham and Women's Hospital Heart and Vascular Center
Associate Professor, Medicine
Associate Director, Clinical Trials Service Unit
University of Washington Medical Center
Vice Chair for Clinical Operations
Department of Medicine
Section of Cardiology
University of Chicago Medicine
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.